Full-Time
Vice President Digital Platforms
Data & Transformation
Altasciences
1,001-5,000 employees
Integrated CRO for early-phase drug development
No salary listed
Montreal, QC, Canada + 2 more
More locations: Cypress, CA, USA | Overland Park, KS, USA
Remote
Bachelor's, Master's
 Data & Analytics (2) |
|---|
| , |
Get referred to Altasciences
See people who can refer or advise you
- A bachelor's degree is required at minimum.
- At least 10 years of experience in senior leadership roles is required.
- At least 10 years of experience leading multidisciplinary technology teams is required.
- Proficiency with Microsoft Word, Excel, Outlook, and PowerPoint is required.
- A demonstrated track record of delivering cross-functional transformation initiatives with measurable business impact is required.
- The ability to work effectively with senior business stakeholders and influence strategy without relying solely on positional authority is required.
- Strong communication, stakeholder management, and executive presence are required.
- The ability to drive strategic change, deliver results, and inspire organizational growth is required.
- Strong understanding of enterprise information technology domains, including infrastructure, networking, security, software development, and operations, is required.
- Working knowledge of modern data and artificial intelligence concepts, including data platforms and pipelines, analytics, machine learning, generative artificial intelligence patterns, and MLOps or artificial intelligence platform basics, is required.
- Familiarity with governance practices around data privacy, information security, and model risk management is required.
- Experience operating in a regulated or highly quality-constrained environment, such as healthcare, life sciences, financial services, or critical infrastructure, is required.
- The ability to create high-performing teams, including attracting, retaining, and developing talent, is required.
- Fluency in English is required because digital solutions, study protocols, designs, and clinical research documents must be written and documented in English; communication occurs frequently with employees across Canada and the United States; and customers outside Quebec are often English-only.
- Design and implement enterprise data architecture and infrastructure that organizes, secures, and makes historical and ongoing scientific and business data usable across sites and systems.
- Drive a data strategy covering data quality, standards, stewardship, and secure access to enable digital transformation.
- Stand up platforms, pipelines, and controls required to safely deploy artificial intelligence and advanced analytics into production workflows.
- Partner with Security, Validation, Quality, and Compliance to ensure artificial intelligence and automation meet regulatory, privacy, and validation expectations.
- Build and manage a high-performing team of data scientists, analytics engineers, and product owners, directly or through a dedicated direct report.
- Create and scale reusable digital solution patterns, such as copilots, workflow automation, and analytics accelerators, rather than one-off proofs of concept.
- Chair or co-chair a technology and data governance council with representation from Legal, Compliance, Security, Quality, and key business units.
- Contribute to policies and guardrails for responsible artificial intelligence use, including model selection, data usage, explainability, and human-in-the-loop oversight.
- Ensure digital solutions meet validation, auditability, and documentation requirements appropriate for the industry.
- Own risk management for digital and artificial intelligence initiatives, including vendor risk, data privacy, and operational resilience.
- Lead cross-functional squads that pair technologists with subject-matter experts to deliver high-value artificial intelligence and digital use cases.
- Drive change-management plans, including communications, training, and role redesign, so teams adopt new tools and ways of working.
- Serve as a visible champion for digital transformation, celebrating wins and removing obstacles.
- Negotiate and manage strategic relationships with key vendors, integrators, and technology partners.
- Monitor emerging technologies and market patterns and translate them into actionable opportunities or risk mitigations for the company.
Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.
Company Size
1,001-5,000
Company Stage
Early VC
Total Funding
$6.7M
Headquarters
Laval, Canada
Founded
1976
Get referred to Altasciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Montréal bioanalytical expansion opens by Q3 2026; Harleysville phase one finishes Q1 2027.
- RegulatoryFlow proof-of-concept in August 2025 automated one-third of nonclinical reports.
- Steel Therapeutics' pivotal tox milestone in 2026 showcases demand for Altasciences' integrated execution.
What critics are saying
- Fargo closed July 2026, forcing 85-90 employees into phased layoffs through September 2026.
- Altasciences still depends on biotech capital spending; sponsor slowdowns hit early-phase utilization first.
- If integrated data quality slips across six facilities, Novo Holdings faces a confidence shock quickly.
What makes Altasciences unique
- Integrated early-phase CRO/CDMO platform spans preclinical, clinical, bioanalysis, and manufacturing.
- Marie-Hélène Raigneau became CEO on February 24, 2026, signaling operating continuity.
- Certara partnership on May 7, 2026 embeds MIDD into execution workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Employee Assistance & Telehealth Programs
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 8%Altasciences expands bioanalytical labs in North america. New and expanded facilities will support rising demand for late-stage clinical bioanalysis. August 11, 2026 Associate Editor Editor's Take: Global pharmaceutical companies continue to pour hundreds of billions of dollars into U.S. manufacturing, R&D and supply chain infrastructure to localize production and bolster domestic capacity. Altasciences is expanding its North American bioanalytical laboratory footprint with a 4,000-square-foot addition to the company's laboratory in Greater Montréal and a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. The lab in Canada is expected to be fully operational by the end of Q3 2026, while construction on the Pennsylvania site will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Supporting demand for sophisticated bioanalytical support. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studies and higher sample volumes while incorporating "state-of-the-art" instrumentation and advanced laboratory automation for pharmacokinetic and pharmacodynamic assay method development, validation, and sample analysis across the clinical phases of drug development. "Our clients are bringing increasingly complex molecules into development, and that is driving unprecedented demand for sophisticated bioanalytical support," said Lynne Le Sauteur, Vice President, Laboratory Sciences, Altasciences. "We're investing ahead of that demand by expanding capacity where sponsors need it most and deploying state-of-the-art instrumentation and automation that enhances speed without compromising quality." The expansion project strengthens Altasciences' broader North American bioanalytical network, which includes established laboratories in Greater Montréal (Quebec), Seattle (Washington), and Columbia (Missouri). Together, these locations provide sponsors with bioanalytical expertise and capacity across the drug development continuum. Meanwhile, network-wide harmonization enables sponsors to leverage capacity across locations, transition work seamlessly between laboratories, and maintain complete confidence in the integrity and consistency of their bioanalytical data. "This investment is about far more than expanding laboratory space," said Robert Sabelli, Co-Chief Operating Officer, Altasciences. "We're building one of the industry's most integrated and scalable bioanalytical networks. As clinical programs become larger, more complex, and increasingly global, sponsors need a partner that can rapidly scale capacity while delivering consistent scientific excellence across every location. That's exactly what we're delivering."
Altasciences completes expansion of research and development laboratory in Harleysville, Pennsylvania. Business Wire Published Aug 04, 2026 Article content LAVAL, Québec - Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. Article content With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey. Article content The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content "With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey," said Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services, Altasciences. "This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively." Article content Top Stories Interested in more newsletters? Browse here. Article content The enhanced laboratory supports phase-appropriate, target product profile (TPP)-driven formulation screening, tailored to both therapeutic areas and routes of administration while remaining agnostic to both. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies. Article content Advanced screening models and integrated analytical testing support nonclinical and clinical readiness, in addition to real-time formulation decisions. By operating in a non-GLP R&D environment, clients will gain flexibility to design and optimize their products before transitioning into regulated studies. Article content "This expansion is not just about building additional space," said Robert Sabelli, Co-Chief Operating Officer, Altasciences. "By continuing to invest in our team, we are growing our scientific talent and connecting our capabilities earlier in the development cycle to better support our clients - and ultimately, the patients they serve." Article content About Altasciences Article content is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across Article content , and formulation, and Article content . Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept - helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visit Article content View source version on businesswire.com: Article content Advertisement 1 This advertisement has not loaded yet.
Altasciences and Evidence Matters have completed a successful proof-of-concept for RegulatoryFlow, an AI platform extending automation from clinical to nonclinical drug development workflows. The collaboration, announced in August 2025, demonstrated accurate parsing of raw and SEND datasets, potentially expediting nonclinical reporting timelines. The current RegFlow version can generate approximately one-third of a typical nonclinical report with high fidelity. The platform has already achieved production of first-draft clinical study reports in clinical workflows. Marie-Hélène Raigneau, CEO of Altasciences, said the milestone helps sponsors move from initial safety assessments to clinical proof-of-concept faster whilst maintaining scientific integrity. Dr Ofer Avital, founder of Evidence Matters, noted the technology creates an AI bridge between nonclinical and clinical phases, freeing resources for higher-value scientific work.
Altasciences and Certara announce strategic partnership to accelerate early drug development. LAVAL, Québec, and Radnor, PA - May 7, 2026 - Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences' Acceleration Platform, the integration of Certara's strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies are refined, and programs are more seamlessly integrated across nonclinical, clinical, bioanalytical, and manufacturing services. "At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision," said Marie-Hélène Raigneau, CEO of Altasciences. "By embedding Certara's modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence. This collaboration is about reducing uncertainty at the moments that matter most." The partnership comes at an opportune time as the FDA continues to advance new guidance supporting more adaptive, data-driven, and real-time drug development approaches, capabilities that integrated MIDD execution models are well positioned to deliver. "This partnership unlocks new opportunities to improve early development decisions for biotech sponsors and their investors," said Jon Resnick, CEO of Certara. "By embedding modeling and simulation directly into execution, we enable faster, more informed decision-making that ultimately benefits patients." Together, Altasciences and Certara are advancing a model-first, fully integrated, and resource-efficient approach to early drug development that accelerates the path to proof of concept for biotech innovators, investors and pharmaceutical companies across the globe. About Altasciences. Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical study programs, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. About Certara. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit Certara Inc. at www.certara.com. Certara contact: Media contact:
ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...